Nanotechnology Now - Press Release: Nanobac Announces Mayo Clinic Initial Results for Nanoparticle and Arterial Calcification Study

Home > Press > Nanobac Announces Mayo Clinic Initial Results for Nanoparticle and Arterial Calcification Study

Abstract:
Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces that scientists at Mayo Clinic, working under a collaborative agreement with Nanobac have cited evidence showing the presence of calcifying nanoparticles (CNPs) in plaque-filled arteries in animal models. This potentially represents a previously unrecognized factor in the development of arteriosclerosis and calcific arterial disease.

Nanobac Announces Mayo Clinic Initial Results for Nanoparticle and Arterial Calcification Study

TAMPA, FL | Posted on May 23rd, 2007

The project seeks to determine if human derived nanoparticles are pathogenic and induce inflammatory and calcific pathologic arterial disease. Scientific evidence increasingly links arterial calcification to the presence of nanosized particles. The project also seeks to confirm prior Nanobac studies, conducted at Washington Hospital, that Nanobac's diagnostic test specifically identifies CNPs.

The study's author, Maria Kraemer, a Mayo Graduate researcher in Rochester, Minn. stated, "The work we are doing with human-derived nanoparticles is important because preliminary studies indicate that they may increase negative responses to arterial injury, possibly leading to blocked arteries and arterial calcification."

Dr. Maniscalco, co-chair of Nanobac, stated: "We believed that CNPs play a major role in pathologic calcification and a multitude of associated disease states such as calcification of arteries and organs. This study, conducted by one of the lead medical and research facilities in the United States, lends credence to our beliefs."

####

About Nanobac Pharmaceuticals, Inc.
Nanobac Pharmaceuticals, Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Experimental Biology is an annual scientific meeting convened by the Federation of American Societies of Experimental Biology, including the American Association of Anatomists; American Physiological Society; American Society for Biochemistry and Molecular Biology; American Society for Investigative Pathology; American Society for Nutrition; and the American Society for Pharmacology and Experimental Therapeutics.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

For more information, please click here

Contacts:
Nanobac Pharmaceuticals, Inc., Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: